IBT full logo.png
Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO
June 30, 2022 11:00 ET | Infant Bacterial Therapeutics AB
Press Release June 30, 2022 Infant Bacterial Therapeutics AB (publ) announced today that Maria Ekdahl has been appointed Chief Financial Officer (CFO) effective September 19, 2022. She will be part...
Infant Bacterial Therapeutics AB utser Maria Ekdahl till CFO
June 30, 2022 11:00 ET | Infant Bacterial Therapeutics AB
Pressmeddelande 30 juni 2022 Infant Bacterial Therapeutics AB (publ) tillkännagav idag att Maria Ekdahl utsetts till Chief Financial Officer (CFO) och tillträder den 19 september 2022. Hon kommer att...
Worldwide Orphan Drugs Industry to 2030 - Use of Orphan Drugs for Novel Conditions/Indications Presents Opportunities
June 15, 2022 05:28 ET | Research and Markets
Dublin, June 15, 2022 (GLOBE NEWSWIRE) -- The "Orphan Drugs Market by Disease Type: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
May 10, 2022 09:05 ET | Clarus Therapeutics Holdings, Inc.
Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2022
May 04, 2022 12:00 ET | Infant Bacterial Therapeutics AB
Message from the CEO IBT's vision is to become an internationally leading company in the development of pharmaceuticals in the areas of premature infants, gastrointestinal diseases and probiotics. ...
Infant Bacterial Therapeutics AB (publ), (IBT) delårsrapport 1 januari – 31 mars 2022
May 04, 2022 12:00 ET | Infant Bacterial Therapeutics AB
VD kommenterar IBT:s vision är att bli ett internationellt ledande företag genom utveckling av läkemedel inom områdena för tidigt födda barn, gastrointestinala sjukdomar och probiotika. Vi har nu...
Annual General Meeting of Infant Bacterial Therapeutics
May 04, 2022 10:00 ET | Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the...
Årsstämma i Infant Bacterial Therapeutics
May 04, 2022 10:00 ET | Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2022 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
April 05, 2022 14:00 ET | Infant Bacterial Therapeutics AB
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted...
Kallelse till årsstämma i Infant Bacterial Therapeutics
April 05, 2022 14:00 ET | Infant Bacterial Therapeutics AB
Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma onsdagen den 4 maj 2022. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...